Email this article 
Crossroad between Obesity and Gastrointestinal Cancers: A Review of Molecular Mechanisms and Interventions
Abstract
Keywords
Full Text:
PDFReferences
Blüher M. Obesity: Global epidemiology and pathogenesis. Nat
Rev Endocrinol 2019;15:288‑98.
Organization WH. Obesity and overweight World Health
Organization Website. World Health Organization Website; 2018.
Lauby‑Secretan B, Scoccianti C, Loomis D, Grosse Y,
Bianchini F, Straif K. Body fatness and cancer—Viewpoint of
the IARC Working Group. N Eng J Med 2016;375:794‑8.
Tahergorabi Z, Moodi M, Zardast M, Ghayravani Z, Tavakoli T.
Metabolic syndrome and the risk of gastrointestinal cancer:
A case‑control study. Asian Pac J Cancer Prev 2018;19:2205‑10.
Nock NL, Thompson CL, Tucker TC, Berger NA, Li L.
Associations between obesity and changes in adult BMI over
time and colon cancer risk. Obesity 2008;16:1099‑104.
Alemán JO, Eusebi LH, Ricciardiello L, Patidar K, Sanyal AJ,
Holt PR. Mechanisms of obesity‑induced gastrointestinal
neoplasia. Gastroenterology 2014;146:357‑73.
sadat Yousefi M, Sharifi‑Esfahani M, Pourgholam‑Amiji N,
Afshar M, Sadeghi‑Gandomani H, Otroshi O, et al. Esophageal
cancer in the world: Incidence, mortality and risk factors.
Biomed Res Ther 2018;5:2504‑17.
Bird‑Lieberman EL, Fitzgerald RC. Early diagnosis of
oesophageal cancer. Br J Cancer 2009;101:1‑6.
Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of
gastrointestinal cancer in Asia; an overview. Gastroenterol
Hepatol Bed Bench 2015;8:19‑27.
Kubo A, Corley DA. Body mass index and adenocarcinomas
of the esophagus or gastric cardia: A systematic review
and meta‑analysis. Cancer Epidemiol Biomarkers Prev
;15:872‑8.
Solaymani‑Dodaran M, Logan R, West J, Card T, Coupland C.
Risk of oesophageal cancer in Barrett’s oesophagus and
gastro‑oesophageal reflux. Gut 2004;53:1070‑4.
Chak A, Falk G, Grady WM, Kinnard M, Elston R, Mittal S,
et al. Assessment of familiality, obesity, and other risk factors
for early age of cancer diagnosis in adenocarcinomas of the
esophagus and gastroesophageal junction. Am J Gastroenterol
;104:1913‑21.
Zheng J, Zhao M, Li J, Lou G, Yuan Y, Bu S, et al.
Obesity‑associated digestive cancers: A review of mechanisms
and interventions. Tumor Biol 2017;39:1010428317695020.
Tahergorabi Z, Khazaei M. The relationship between
inflammatory markers, angiogenesis, and obesity. ARYA
Atheroscler 2013;9:247‑53.
Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF
system in cancer growth and metastasis: Overview and recent
insights. Endocr Rev 2007;28:20‑47.
Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin
receptor isoforms and insulin receptor/insulin‑like growth
factor receptor hybrids in physiology and disease. Endocr Rev
;30:586‑623.
El Yafi F, Winkler R, Delvenne P, Boussif N, Belaiche J,
Louis E. Altered expression of type I insulin-like growth factor
receptor in Crohn’s disease. Clin Exp Immunol 2005;139:526‑33.
Gallagher EJ, LeRoith D. Minireview: IGF, insulin, and cancer.
Endocrinology 2011;152:2546‑51.
Doyle SL, Donohoe CL, Finn SP, Howard JM, Lithander FE,
Reynolds JV, et al. IGF‑1 and its receptor in esophageal cancer:
Association with adenocarcinoma and visceral obesity. Am J
Gastroenterol 2012;107:196‑204.
Francois F, Roper J, Goodman AJ, Pei Z, Ghumman M,
Mourad M, et al. The association of gastric leptin with
oesophageal inflammation and metaplasia. Gut 2008;57:16‑24.
Howard J, Beddy P, Ennis D, Keogan M, Pidgeon G,
Reynolds J. Associations between leptin and adiponectin receptor
upregulation, visceral obesity and tumour stage in oesophageal
and junctional adenocarcinoma. Br J Surg 2010;97:1020‑7.
Duggan C, Onstad L, Hardikar S, Blount PL, Reid BJ,
Vaughan TL. Association between markers of obesity
and progression from Barrett’s esophagus to esophageal
adenocarcinoma. Clin Gastroenterol Hepatol 2013;11:934‑43.
Unger RH, Scherer PE. Gluttony, sloth and the metabolic
syndrome: A roadmap to lipotoxicity. Trends Endocrinol Metab
;21:345‑52.
Rubenstein JH, Kao JY, Madanick RD, Zhang M, Wang M,
Spacek MB, et al. Association of adiponectin multimers with
Barrett’s oesophagus. Gut 2009;58:1583‑9.
Ogunwobi O, Beales I. Leptin stimulates the proliferation of
human oesophageal adenocarcinoma cells via HB‑EGF and
TGFα mediated transactivation of the epidermal growth factor
receptor. Br J Biomed Sci 2008;65:121‑7.
Thompson OM, Beresford SA, Kirk EA, Bronner MP,
Vaughan TL. Serum leptin and adiponectin levels and
risk of Barrett’s esophagus and intestinal metaplasia of
the gastroesophageal junction. Obesity (Silver Spring)
;18:2204‑11.
Nasrollahzadeh D, Malekzadeh R, Ploner A, Shakeri R,
Sotoudeh M, Fahimi S, et al. Variations of gastric corpus
microbiota are associated with early esophageal squamous cell
carcinoma and squamous dysplasia. Sci Rep 2015;5:8820.
Patel T, Bhattacharya P, Das S. Gut microbiota: An indicator
to gastrointestinal tract diseases. J Gastrointest Cancer
;47:232‑8.
Yang L, Francois F, Pei Z. Molecular pathways: Pathogenesis
and clinical implications of microbiome alteration in esophagitis
and Barrett esophagus. Clin Cancer Res 2012;18:2138‑44.
Lee S‑J, Park H, Chang JH, Conklin JL. Generation of nitric
oxide in the opossum lower esophageal sphincter during
physiological experimentation. Yonsei Med J 2006;47:223‑9.
Farhood B, Geraily G, Alizadeh A. Incidence and mortality of
various cancers in Iran and compare to other countries: A review
article. Iran J Public Health 2018;47:309‑16.
Chow W‑H, Blot WJ, Vaughan TL, Risch HA, Gammon MD,
Stanford JL, et al. Body mass index and risk of adenocarcinomas
of the esophagus and gastric cardia. J Natl Cancer Inst
;90:150‑5.
Crew KD, Neugut AI. Epidemiology of gastric cancer. World J
Gastroenterol 2006;12:354‑62.
Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883‑90.
Rastaghi S, Jafari‑Koshki T, Mahaki B, Bashiri Y, Mehrabani K,
Soleimani A. Trends and risk factors of gastric cancer in Iran
(2005–2010). Int J Prev Med 2019;10:79.
Helicobacter and Cancer Collaborative Group. Gastric cancer
and Helicobacter pylori: A combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347‑53.
De Ostrovich KK, Lambertz I, Colby JK, Tian J, Rundhaug JE,
Johnston D, et al. Paracrine overexpression of insulin‑like
growth factor‑1 enhances mammary tumorigenesis in vivo. Am J
Pathol 2008;173:824‑34.
Huang YF, Shen MR, Hsu KF, Cheng YM, Chou CY. Clinical
implications of insulin‑like growth factor 1 system in early‑stage
cervical cancer. Br J Cancer 2008;99:1096‑102.
Zhao R, DeCoteau JF, Geyer CR, Gao M, Cui H, Casson AG.
Loss of imprinting of the insulin‑like growth factor II (IGF2)
gene in esophageal normal and adenocarcinoma tissues.
Carcinogenesis 2009;30:2117‑22.
Wang HB, Zhou CJ, Song SZ, Chen P, Xu WH, Liu B,
et al. Evaluation of Nrf2 and IGF‑1 expression in benign,
premalignant and malignant gastric lesions. Pathol Res Pract
;207:169‑73.
Liu W, Yu R, Zhou G. Expression and significance of IGF‑1R
and VEGF in gastric carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue
Za Zhi 2009;25:529‑30.
Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T,
Shirao K, et al. Clinical significance of insulin‑like growth factor
type 1 receptor and epidermal growth factor receptor in patients
with advanced gastric cancer. Oncology 2008;74:76‑83.
Zhao X, Huang K, Zhu Z, Chen S, Hu R. Correlation between
expression of leptin and clinicopathological features and
prognosis in patients with gastric cancer. J Gastroenterol Hepatol
;22:1317‑21.
Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol
;207:12‑22.
Tahergorabi Z, Khazaei M. Leptin and its cardiovascular effects:
Focus on angiogenesis. Adv Biomed Res 2015;4:79.
Zhao L, Vogt PK. Class I PI3K in oncogenic cellular
transformation. Oncogene 2008;27:5486‑96.
Ericksen RE, Rose S, Westphalen CB, Shibata W, Muthupalani S,
Tailor Y, et al. Obesity accelerates Helicobacter felis‑induced
gastric carcinogenesis by enhancing immature myeloid cell
trafficking and TH17 response. Gut 2014;63:385‑94.
Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, et al.
Involvement of proinflammatory cytokines IL‑1β and IL‑6
in progression of human gastric carcinoma. Anticancer Res
;25:709‑13.
Kuroda T, Kitadai Y, Tanaka S, Yang X, Mukaida N,
Yoshihara M, et al. Monocyte chemoattractant protein‑1
transfection induces angiogenesis and tumorigenesis of gastric
carcinoma in nude mice via macrophage recruitment. Clin
Cancer Res 2005;11:7629‑36.
Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, et al.
Prognostic significance of vascular endothelial growth
factor immunohistochemical expression in gastric cancer:
A meta‑analysis. Mol Biol Rep 2012;39:9473‑84.
McCarthy T, O'Neil BH. Angiogenesis inhibitors in gastric
cancer. J Orphan Drugs: Res Rev. 2014;4:55-61.
Gandomani HS, Aghajani M, Mohammadian‑Hafshejani A,
Tarazoj AA, Pouyesh V, Salehiniya H. Colorectal cancer in the
world: Incidence, mortality and risk factors. Biomed Res Ther
;4:1656‑75.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M.
Body‑mass index and incidence of cancer: A systematic review
and meta‑analysis of prospective observational studies. Lancet
;371:569‑78.
Ouban A, Muraca P, Yeatman T, Coppola D. Expression and
distribution of insulin‑like growth factor‑1 receptor in human
carcinomas. Hum Pathol 2003;34:803‑8.
Valentinis B, Baserga R. IGF‑I receptor signalling in
transformation and differentiation. Mol Pathol 2001;54:133‑7.
Guo YS, Narayan S, Yallampalli C, Singh P. Characterization
of insulinlike growth factor I receptors in human colon cancer.
Gastroenterology 1992;102:1101‑8.
Singh P, Rubin N. Insulinlike growth factors and binding proteins
in colon cancer. Gastroenterology 1993;105:1218‑37.
Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S,
Linseisen J, et al. Serum levels of IGF-I, IGFBP-3 and colorectal
cancer risk: Results from the EPIC cohort, plus a meta-analysis
of prospective studies. Int J Cancer 2010;126:1702‑15.
Karczewski J, Begier‑Krasińska B, Staszewski R, Popławska E,
Gulczynska‑Elhadi K, Dobrowolska A. Obesity and the risk of
gastrointestinal cancers. Dig Dis Sci 2019;64:2740‑9.
Donohoe C, Pidgeon G, Lysaght J, Reynolds J. Obesity and
gastrointestinal cancer. Br J Surg 2010;97:628‑42.
Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP,
Platz EA. C-reactive protein and colorectal cancer risk:
A systematic review of prospective studies. Int J Cancer
;123:1133‑40.
Tahergorabi Z, Khazaei M, Moodi M, Chamani E. From obesity
to cancer: A review on proposed mechanisms. Cell Biochem
Funct 2016;34:533‑45.
Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M,
Kaplan RC, et al. Adipokines linking obesity with colorectal
cancer risk in postmenopausal women. Cancer Res
;72:3029‑37.
Endo H, Hosono K, Uchiyama T, Sakai E, Sugiyama M,
Takahashi H, et al. Leptin acts as a growth factor for colorectal
tumours at stages subsequent to tumour initiation in murine
colon carcinogenesis. Gut 2011;60:1363‑71.
Drew JE. Molecular mechanisms linking adipokines to
obesity‑related colon cancer: Focus on leptin. Proc Nutr Soc
;71:175‑80.
Padidar S, Farquharson AJ, Williams LM, Kelaiditi E,
Hoggard N, Arthur JR, et al. Leptin up-regulates
pro-inflammatory cytokines in discrete cells within mouse colon.
J Cell Physiol 2011;226:2123‑30.
Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S,
Yoneda K, et al. Adiponectin inhibits colorectal cancer cell
growth through the AMPK/mTOR pathway. Int J Oncol
;34:339‑44.
Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang S‑H, et al.
Adiponectin represses colon cancer cell proliferation via
AdipoR1‑and‑R2‑mediated AMPK activation. Mol Endocrinol
;24:1441‑52.
Saxena A, Baliga MS, Ponemone V, Kaur K, Larsen B,
Fletcher E, et al. Mucus and adiponectin deficiency: Role in
chronic inflammation‑induced colon cancer. Int J Colorectal Dis
;28:1267‑79.
Konda B, Shum H, Rajdev L. Anti‑angiogenic agents in
metastatic colorectal cancer. World J Gastrointest Oncol
;7:71‑86.
Bendardaf R, El‑Serafi A, Syrjänend K, Collan Y, Pyrhönen S.
The effect of vascular endothelial growth factor‑1 expression on
survival of advanced colorectal cancer patients. Libyan J Med
;12:1290741.
Nandikolla AG, Rajdev L. Targeting angiogenesis in
gastrointestinal tumors: Current challenges. Transl Gastroenterol
Hepatol 2016;1:67.
Tahergorabi Z, Rashidi B, Khazaei M. Ghrelin does not modulate angiogenesis in matrigel plug in normal and diet‑induced obese mice. J Res Med Sci 2013;18:939‑42.
Strassburg S, Anker SD, Castaneda TR, Burget L, Perez‑Tilve D,
Pfluger PT, et al. Long‑term effects of ghrelin and ghrelin
receptor agonists on energy balance in rats. Am J Physiol
Endocrinol Metab 2008;295:E78‑84.
Waseem T, Duxbury M, Ashley SW, Robinson MK. Ghrelin
promotes intestinal epithelial cell proliferation through PI3K/Akt
pathway and EGFR trans‑activation both converging to ERK 1/2
phosphorylation. Peptides 2014;52:113‑21.
Yu H, Xu G, Fan X. The effect of ghrelin on cell proliferation
in small intestinal IEC‑6 cells. Biomed Pharmacother
;67:235‑9.
Kew MC. Hepatocellular carcinoma: Epidemiology and risk
factors. J Hepatocell Carcinoma 2014;1:115‑25.
Mittal S, El‑Serag HB. Epidemiology of HCC: Consider the
population. J Clin Gastroenterol 2013;47(Suppl):S2‑6.
Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM. Burden of
hepatocellular carcinoma in Iran; Bayesian projection and trend
analysis. Asian Pac J Cancer Prev 2010;11:859‑62.
Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty
liver disease: Biochemical, metabolic, and clinical implications.
Hepatology 2010;51:679‑89.
Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk:
New mechanistic insights from epidemiology. Nat Rev Cancer
;15:484‑98.
Wong VWS, Wong GLH, Tsang SWC, Fan T, Chu WCW,
Woo J, et al. High prevalence of colorectal neoplasm in patients
with non‑alcoholic steatohepatitis. Gut 2011;60:829‑36.
Hwang ST, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, et al.
Relationship of non-alcoholic fatty liver disease to colorectal
adenomatous polyps. J Gastroenterol Hepatol 2010;25:562‑7.
Barash H, Gross ER, Edrei Y, Ella E, Israel A, Cohen I, et al.
Accelerated carcinogenesis following liver regeneration is
associated with chronic inflammation‑induced double‑strand
DNA breaks. Proc Natl Acad Sci 2010;107:2207‑12.
Muriel P. Role of free radicals in liver diseases. Hepatol Int
;3:526‑36.
Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in
non‑alcoholic fatty liver disease: An emerging menace. J Hepatol
;56:1384‑91.
Calle EE, Kaaks R. Overweight, obesity and cancer:
Epidemiological evidence and proposed mechanisms. Nat Rev
Cancer 2004;4:579‑91.
Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S,
Fukui K, et al. Hypoadiponectinemia accelerates hepatic tumor
formation in a nonalcoholic steatohepatitis mouse model.
J Hepatol 2007;47:556‑64.
Saxena NK, Fu PP, Nagalingam A, Wang J, Handy J,
Cohen C, et al. Adiponectin modulates C-jun N-terminal kinase
and mammalian target of rapamycin and inhibits hepatocellular
carcinoma. Gastroenterology. 2010;139:1762-73, 1773.e1-5.
Sharma D, Wang J, Fu PP, Sharma S, Nagalingam A, Mells J,
et al. Adiponectin antagonizes the oncogenic actions of leptin in
hepatocellular carcinogenesis. Hepatology 2010;52:1713‑22.
Aleksandrova K, Boeing H, Nöthlings U, Jenab M, Fedirko V,
Kaaks R, et al. Inflammatory and metabolic biomarkers and risk
of liver and biliary tract cancer. Hepatology 2014;60:858‑71.
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M,
Niederegger H, et al. Visfatin, an adipocytokine with
proinflammatory and immunomodulating properties. J Immunol
;178:1748‑58.
Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I,
Kaser S, et al. Effects of weight loss induced by
bariatric surgery on hepatic adipocytokine expression.
J Hepatol 2009;51:765‑77.
Adolph T, Grander C, Grabherr F, Tilg H. Adipokines and
non‑alcoholic fatty liver disease: Multiple interactions. Int J Mol
Sci 2017;18:1649.
Jamali R, Razavizade M, Arj A, Aarabi MH. Serum adipokines
might predict liver histology findings in non‑alcoholic fatty liver
disease. World J Gastroenterol 2016;22:5096‑103.
Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O,
et al. Serum levels of omentin, chemerin and adipsin in patients
with biopsy‑proven nonalcoholic fatty liver disease. Scand J
Gastroenterol 2011;46:91‑7.
Pohl R, Haberl EM, Rein-Fischboeck L, Zimny S, Neumann M,
Aslanidis C, et al. Hepatic chemerin mRNA expression is
reduced in human nonalcoholic steatohepatitis. Eur J Clin Invest
;47:7‑18.
Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV,
Mantzoros CS. Irisin in patients with nonalcoholic fatty liver
disease. Metabolism 2014;63:207‑17.
Hursting SD, DiGiovanni J, Dannenberg AJ, Azrad M,
LeRoith D, Demark‑Wahnefried W, et al. Obesity, energy
balance, and cancer: New opportunities for prevention. Cancer
Prev Res (Phila) 2012;5:1260‑72.
Lashinger LM, Ford NA, Hursting SD. Interacting inflammatory
and growth factor signals underlie the obesity‑cancer link. J Nutr
;144:109‑13.
Zahedi H, Djalalinia S, Asayesh H, Mansourian M, Abdar ZE,
Gorabi AM, et al. A higher dietary inflammatory index score
is associated with a higher risk of incidence and mortality of
cancer: A comprehensive systematic review and meta‑analysis.
Int J Prev Med 2020;11:15.
Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L,
Wener MH, et al. Effects of a caloric restriction weight loss diet
and exercise on inflammatory biomarkers in overweight/obese
postmenopausal women: A randomized controlled trial. Cancer
Res 2012;72:2314‑26.
Foster-Schubert KE, Alfano CM, Duggan CR, Xiao L,
Campbell KL, Kong A, et al. Effect of diet and exercise, alone
or combined, on weight and body composition in overweight-toobese postmenopausal women. Obesity 2012;20:1628‑38.
Quang N, Hien NQ, Quang NT, Chung NT. Active Lifestyle
Patterns Reduce the Risk of Colorectal Cancer in the North of
Vietnam: A Hospital-Based Case-Control Study. Cancer Control.
;26:1073274819864666.
Oruç Z, Kaplan MA. Effect of exercise on colorectal cancer
prevention and treatment. World J Gastrointest Oncol
;11:348‑66.
Harriss D, Atkinson G, Batterham A, George K,
Tim Cable N, Reilly T, et al. Lifestyle factors and colorectal
cancer risk (2): A systematic review and meta-analysis of
associations with leisure-time physical activity. Colorectal
Dis 2009;11:689‑701.
Kelly SA, Zhao L, Jung K‑C, Hua K, Threadgill DW, Kim Y,
et al. Prevention of tumorigenesis in mice by exercise is
dependent on strain background and timing relative to carcinogen exposure. Sci Rep 2017;7:1‑11. doi: 10.1038/srep43086.
Wang X, You T, Murphy K, Lyles MF, Nicklas BJ. Addition of
exercise increases plasma adiponectin and release from adipose
tissue. Med Sci Sports Exerc 2015;47:2450‑5.
Kelly KR, Navaneethan SD, Solomon TP, Haus JM, Cook M,
Barkoukis H, et al. Lifestyle‑induced decrease in fat mass
improves adiponectin secretion in obese adults. Med Sci Sports
Exerc 2014;46:920‑6.
Abbenhardt C, McTiernan A, Alfano CM, Wener MH, Campbell KL, Duggan C, et al. Effects of individual and
combined dietary weight loss and exercise interventions in
postmenopausal women on adiponectin and leptin levels. J Intern
Med 2013;274:163‑75.
Ulrich CM, Himbert C, Holowatyj AN, Hursting SD. Energy
balance and gastrointestinal cancer: Risk, interventions,
outcomes and mechanisms. Nat Rev Gastroenterol Hepatol
;15:683‑98.